Related references
Note: Only part of the references are listed.QSAR analysis of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives isocitrate dehydrogenase inhibitors using Topomer CoMFA and HQSAR methods
Jian-Bo Tong et al.
MOLECULAR DIVERSITY (2022)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein et al.
BLOOD (2021)
IDH1/2mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis
Badder Kattih et al.
LEUKEMIA (2021)
Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms
Yingqing Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Qianqian Wang et al.
PHARMACOLOGICAL RESEARCH (2021)
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
Marina Radoul et al.
METABOLITES (2021)
Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment
Na Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Prognostic significance of concurrent gene mutations i n intensively treated patients with IDH-mutated AML: an ALFA study
Matthieu Duchmann et al.
BLOOD (2021)
Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
Jason M. Rohde et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
Shuang Liu et al.
COMMUNICATIONS BIOLOGY (2021)
Towards precision medicine for AML
Hartmut Dohner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
IDH Inhibitors in AML-Promise and Pitfalls
Hannah McMurry et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia
Jingtao Lu et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells
Christian Gerecke et al.
EPIGENETICS (2020)
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor
Chujiao Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma
Nissreen Mohammad et al.
HISTOPATHOLOGY (2020)
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Anuhar Chaturvedi et al.
LEUKEMIA (2020)
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Alessandra Scagliola et al.
ANTIOXIDANTS & REDOX SIGNALING (2020)
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
Justin A. Caravella et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Bin Fan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Immunotherapy for glioma: Current management and future application
Shengchao Xu et al.
CANCER LETTERS (2020)
Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenaseR132Hmutation
Mika M. Tabata et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2020)
Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1)
Chung Hyo Kang et al.
ANTICANCER RESEARCH (2020)
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Michael Heuser et al.
LEUKEMIA (2020)
Sphingolipid Pathway as a Source of Vulnerability in IDH1mut Glioma
Tyrone Dowdy et al.
CANCERS (2020)
Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma
Nah Ihm Kim et al.
FRONTIERS IN ONCOLOGY (2020)
Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
Katharina J. Wenger et al.
CANCERS (2020)
Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
Yuwei Wang et al.
FRONTIERS IN PHARMACOLOGY (2020)
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Alessandro Fiorentini et al.
ONCOLOGY AND THERAPY (2020)
Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening
Zhe Duan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors
Jian Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo
Panli Jia et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
Makoto Nakagawa et al.
ONCOGENE (2019)
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
Xiaoqi Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration
Hengyi Cao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening
Fangxia Zou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
Qiangang Zheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1
Mengzhu Zheng et al.
BIOORGANIC CHEMISTRY (2018)
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
Bin Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Fangrui Wu et al.
MEDICINAL CHEMISTRY (2018)
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors
Qian Zhao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
Hanumantha Rao Madala et al.
CANCERS (2018)
3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation
Yuanyuan Hu et al.
ARCHIV DER PHARMAZIE (2018)
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Rui Ma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Dan Ye et al.
TRENDS IN CANCER (2018)
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
A. Chaturvedi et al.
LEUKEMIA (2017)
Glioma Subclassifications and Their Clinical Significance
Ricky Chen et al.
NEUROTHERAPEUTICS (2017)
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
Julian R. Levell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Young Shin Cho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Zhentao Yang et al.
CELL REPORTS (2017)
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1
Tianfang Ma et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
Qiangang Zheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery
Alan Merk et al.
CELL (2016)
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells
Stuart Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1
Jason M. Law et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
Fangrui Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Ujunwa C. Okoye-Okafor et al.
NATURE CHEMICAL BIOLOGY (2015)
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
Pu Wang et al.
CELL REPORTS (2015)
Glioma
Michael Weller et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Serena Pellegatta et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule
Gejing Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
Mindy I. Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure-Activity Relationship, and Selective Antitumor Activity
Zhen Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi et al.
BLOOD (2013)
Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors
Christopher J. Pirozzi et al.
CANCER CELL (2013)
Drug repositioning by structure-based virtual screening
Dik-Lung Ma et al.
CHEMICAL SOCIETY REVIEWS (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Baisong Zheng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Peppi Koivunen et al.
NATURE (2012)
Enzyme redesign guided by cancer-derived IDH1 mutations
Zachary J. Reitman et al.
NATURE CHEMICAL BIOLOGY (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H
Bei Yang et al.
CELL RESEARCH (2010)
Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents
Emily S. Jungheim et al.
FERTILITY AND STERILITY (2010)
THE VALUE OF DRUG REPOSITIONING IN THE CURRENT PHARMACEUTICAL MARKET
Edward L. Tobinick
DRUG NEWS & PERSPECTIVES (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Substrate-free structure of a monomeric NADP isocitrate dehydrogenase: An open conformation phylogenetic relationship of isocitrate dehydrogenase
F Imabayashi et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea (Withdrawn Paper. 1996, art. no. CD000056.pub2)
E Hughes et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2005)
Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea (Withdrawn paper. 1996, art. no. CD000056)
E Hughes et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2005)
Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea (Withdrawn Paper. 1996, art. no. CD000056.pub2)
E Hughes et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2005)
Share Paper
